Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants

PURPOSE: Diabetic macular oedema (DMO) is a leading cause of blindness in working-age adults. Slow-release, nonbioerodible fluocinolone acetonide (FAc) implants have shown efficacy in the treatment of DMO; however, the National Institute for Health and Care Excellence recommends that FAc should be u...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Y, Bailey, C, Holz, F G, Eter, N, Weber, M, Baker, C, Kiss, S, Menchini, U, Ruiz Moreno, J M, Dugel, P, Lotery, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565956/
https://www.ncbi.nlm.nih.gov/pubmed/26113503
http://dx.doi.org/10.1038/eye.2015.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565956/
https://www.ncbi.nlm.nih.gov/pubmed/26113503
http://dx.doi.org/10.1038/eye.2015.98

Ejemplares similares